Dermafirm USA announces the U.S. launch of prestige K-beauty skincare line, BIOTOC, and they say it’s the new noninvasive alternative to injectables.
Dermafirm USA, the North American arm of Dermafirm, Inc., a South Korean cosmeceutical company, recently announced the U.S. launch of BIOTOC as a noninvasive alternative to injectables.
With product sales initially slated for a B2B model, the company quickly moved to D2C due to the COVID-19 pandemic and subsequent stay-at-home orders.
"BIOTOC offers visible results, as a topical alternative to injectables that can be applied at home,” says Paula Park, CEO and founder of Dermafirm USA, in the release. “Given the business reality of increased consumer demand for safe, natural and effective DIY products, and the unknown of when businesses would re-open, we switched gears. We repositioned our new prestige skincare line's direction from B2B to D2C and haven't looked back."
First launching in June of this year in South Korea, BIOTOC is a professional grade, anti-aging facial ampoule that is more concentrated than a serum, with ingredients including astaxanthin, professional grade cross-linked hyaluronic acid, three peptides, collagen hydrolysates, and ceramide.
“Astaxanthin, known as the most robust antioxidant available, is proven to be 6,000 times more powerful than Vitamin C, 800 times stronger than CoQ10, 550 times stronger than Vitamin E, 75 times stronger than alpha lipoic acid and 40 times stronger than beta-carotene,” according to the press release.
The line is said to increase the skin’s energy production, improve the appearance of wrinkles, brighten and restore skin elasticity, according to Dermafirm.